Horizon (HZNP) Shares Jump As FDA Grants Fast Track Designation to Actimmune

Horizon Pharma plc (HZNP) is a solid gainer this session, as its shares are up nearly 5%. The surge came after the company said that Actimmune (interferon gamma-1b), its experimental Friedreich’s ataxia treatment, has received fast-track designation from the FDA, a move that could speed approval. “We commend the FDA for granting Fast Track designation for Actimmune […] View the full post at: Horizon (HZNP) Shares Jump As FDA Grants Fast Track Designation to Actimmune Related posts: Atlas Pipeline (APL) Shares Soar On Nat Gas Asset Sale